Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gabriela Gruia"'
Autor:
Richard M. Goldberg, Gabriela Gruia, Gary Elfring, Mace L. Rothenberg, Rakesh Goel, Donghua Yin, Larry J. Schaaf, Lisa A. Hammond, Stuart J. Tipping, Barbara A. Duncan, Linda D. Compton, J. Patrick McGovren, Langdon L. Miller, Amarnath Sharma, John G. Kuhn, Nicoletta Pirotta, Laura Cisar
Publikováno v:
Clinical Cancer Research. 12:3782-3791
Purpose: To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule. Experimental Design: Patients with solid tumors who had impaired liver function were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8896bbf5fbfd55ba221b8fbf37c9370b
https://doi.org/10.1158/1078-0432.ccr-05-2152
https://doi.org/10.1158/1078-0432.ccr-05-2152
Autor:
Laura Cisar, Nicoletta Orlando, Mark R. Green, Wilson H. Miller, Langdon L. Miller, Caio Max S. Rocha Lima, Adele Morganti, Gabriela Gruia, G. Mark Jeffrey, Robert Rotche
Publikováno v:
Journal of Clinical Oncology. 22:3776-3783
Purpose This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monotherapy (GEM) in patients with chemotherapy-naive, locally advanced or metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8083a6376626b2ddd16402c911d0fc40
https://doi.org/10.1200/jco.2004.12.082
https://doi.org/10.1200/jco.2004.12.082
Autor:
Jean-Yves Douillard, Gary Elfring, May Alakl, Gabriela Gruia, Langdon L. Miller, Lucile Awad, Paula K. Locker, Leonard B. Saltz, Nicoletta Pirotta
Publikováno v:
The Oncologist. 6:81-91
Background. Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV). This demonstrated activity of irinotecan as effective second-line therapy for color
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e21d7a1421b7376c4f48c2fbfc51fbc
https://doi.org/10.1634/theoncologist.6-1-81
https://doi.org/10.1634/theoncologist.6-1-81
Publikováno v:
New England Journal of Medicine. 362:561-563
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f9a19f4c65b82fad2b83b72aac0ef28
https://doi.org/10.1056/nejmc0911892
https://doi.org/10.1056/nejmc0911892
Autor:
V. M. M. Herben, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Jan H.M. Schellens, Laurent Vernillet, M. Swart, Gabriela Gruia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(6)
PURPOSE: To evaluate the feasibility of administering irinotecan as a continuous intravenous infusion for 14 to 21 days. PATIENTS AND METHODS: Patients with solid tumors refractory to standard therapy received continuous infusions of irinotecan by me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46df0ef4407f970f557c45968b59c412
https://pubmed.ncbi.nlm.nih.gov/10561231
https://pubmed.ncbi.nlm.nih.gov/10561231
Autor:
Langdon L. Miller, Leonard B. Saltz, Samit Hirawat, Jean-Yves Douillard, Gabriela Gruia, Gary Elfring
Publikováno v:
Journal of Clinical Oncology. 22:3503-3503
3503 Background: OS has been the 1o endpoint for phase III MCRC registration trials. However, increasing numbers of efficacious agents have extended OS and added therapeutic complexity. Evaluation of new drugs based on OS may be impeded by larger sam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6f7a7b909250bb460170cce0ffdd35c
https://doi.org/10.1200/jco.2004.22.90140.3503
https://doi.org/10.1200/jco.2004.22.90140.3503
Autor:
J. H. M. Schellens, Gabriela Gruia, W.W. ten Bokkel Huinink, V. M. M. Herben, J. Béynen, M. Swart
Publikováno v:
European Journal of Cancer. 33:S253
CPT11 isa a topoisomerase I inhibitor with substantial anti tumor activity. Preclinical data suggest that prolonged exposure has better efficacy and possibly less toxicity. A dose-escalation phase I study of CPT11 continuous I.v (c.i.v.) over 14-days
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59e104db26876c32bffb58826150ac9d
https://doi.org/10.1016/s0959-8049(97)86053-4
https://doi.org/10.1016/s0959-8049(97)86053-4